Ask about this productRelated genes to: Pax5 antibody
- Gene:
- PAX5 NIH gene
- Name:
- paired box 5
- Previous symbol:
- -
- Synonyms:
- BSAP
- Chromosome:
- 9p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-11-03
- Date modifiied:
- 2019-04-23
Related products to: Pax5 antibody
Related articles to: Pax5 antibody
- Cases of diffuse large B-cell lymphoma (DLBCL) of the uterus co-expressing CD5 are exceedingly rare and diagnostically challenging due to its nonspecific clinical and radiological features, which often mimic other uterine malignancies. This study retrospectively analyzes the cytopathological and histopathological characteristics of this entity in uterine cavity drainage fluid to facilitate its recognition. - Source: PubMed
Publication date: 2026/04/07
Yu QinlingFu ChaojuJing FengZeng Ying - Transcriptome sequencing (RNA-seq) is emerging as a diagnostic standard for B-cell precursor acute lymphoblastic leukemia (B-ALL). Expression-based classifiers reach ~95% accuracy, but reproducible end-to-end solutions that also integrate transcript-derived genomic drivers and quantitative virtual karyotyping are lacking. We developed IntegrateALL, a Snakemake pipeline that standardizes RNA-seq analysis from FASTQ to rule-based subtype assignment across 26 WHO-HAEM5/ICC entities by integrating expression-based subtype prediction, gene fusion-/hotspot SNV calling, and virtual karyotyping. We introduce KaryALL, a machine learning classifier that uses normalized expression and minor-allele-frequency features (RNASeqCNV), to distinguish near-haploid, hypodiploid, and high-hyperdiploid B-ALL and chromosome-21 gains/iAMP21 (accuracy: 0.98/F1 score: 0.96 on 615 independent test samples). SNP-array concordance supported RNA-based karyotyping. Applied to 774 unselected B-ALL cases, IntegrateALL yielded unambiguous subtype assignments in 81.5%, based on concordance of gene expression class with a defining driver (75.3% of all cases) or, in selected cases, high-confidence expression-based classification alone (6.2%); the remainder (18.5%) were flagged for manual curation. Independent validation (three cohorts; = 436, including pediatric cases) reproduced these distributions. Across all patients ( = 1210), 2.6% harbored two subtype-defining drivers, including hyperdiploidy in fusion-driven subtypes, where it was not expected, or subtype-defining SNVs (e.g., P80R/ N159Y) co-occurring with -positive/-like, -, or -fusions. In most dual-driver cases, one subtype gene expression signature predominated, consistent with oncogenic hierarchies, but also with the possibility of technical artifacts, which should prompt individual orthogonal validations. IntegrateALL provides an adaptable fully reproducible workflow for molecular B-ALL characterization by systematically integrating genomic drivers and downstream gene regulation. - Source: PubMed
Publication date: 2026/04/16
Wolgast NadineBeder ThomasMondal MayukhWalter WenckeHutter StephanBendig SonjaKässens JanHansen Björn-ThoreIben KatharinaWolf SebastianCremer AnjaliBarz MalwineNeumann MartinGökbuget NicolaHaferlach ClaudiaBrüggemann MonikaBaldus Claudia DHartmann Alina MBastian Lorenz - Lymph node metastasis (LMN) is a key factor in the poor clinical prognosis of patients with gastric adenocarcinoma (GAC), but the underlying cellular regulatory networks and molecular mechanisms are not fully understood. - Source: PubMed
Publication date: 2026/04/16
Chen ShiWang FengWang LiXingGong YunLi YiJunXu QingWenHe LinXingQi YuXingLi ShuMinXiong HangLiao ChenSun Feng - - Source: PubMed
Publication date: 2026/04/15
Bacos KarlPerfilyev AlexanderKaragiannopoulos AlexandrosCowan ElaineOfori Jones KBertonnier-Brouty LudivineRönn TinaLindqvist AndreasLuan ChengRuhrmann SabrinaNgara MtakaiNilsson ÅsaGheibi SevdaLyons Claire LLagerstedt Jens OBarghouth MohammadEsguerra Jonathan LsVolkov PetrFex MalinMulder HindrikWierup NilsKrus UlrikaArtner IsabellaEliasson LenaPrasad Rashmi BCataldo Luis RodrigoLing Charlotte - Lymphoma is a diverse group of blood cancers arising from lymphoid tissue, characterized by distinct morphological, immunophenotypic, genetic and clinical variations. Therefore, it is of interest to identify which immunohistochemical (IHC) markers were minimum essentials markers to enable classification and prognostication in lymphoid malignancies. The retrospective study used a primary panel of monoclonal antibodies consisting of CD3 and CD5, CD20, CD10, CD45, PAX-5 and Ki-67 on 88 lymphoma cases. It was found that B-cell lymphomas were highly labeled with CD20, CD45, PAX-5, whereas T-cell lymphomas were heavily labeled with CD3, CD5. There were high levels of Ki-67 proliferation indices in the aggressive lymphoma sub-types e.g. Diffuse Large B-Cell Lymphoma and T-cell lymphomas. The study helps to recommend a restricted yet cost-effective panel of IHC markers to attain reliable diagnosis and prognosis of lymphoma particularly in lower resource settings. - Source: PubMed
Publication date: 2026/01/31
Ghanghoria ShikhaGhanghoria ArvindSai Chownika Gulladurthi PrudhviThakur AashitaVerma Tarun PrakashParmar Sachin